1. Attenuated suppression of lipolysis explains the increases in triglyceride secretion and concentration associated with basal insulin peglispro relative to insulin glargine treatment in patients with type 1 diabetes. Issue 2 (10th October 2017) Authors: Johansen, Rakel F.; Søndergaard, Esben; Linnebjerg, Helle; Garhyan, Parag; Lam, Eric C. Q.; Porksen, Niels; Jacober, Scott J.; Nielsen, Søren Journal: Diabetes, obesity & metabolism Issue: Volume 20:Issue 2(2018) Page Start: 419 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Basal insulin peglispro increases lipid oxidation, metabolic flexibility, thermogenesis and ketone bodies compared to insulin glargine in subjects with type 1 diabetes mellitus. Issue 5 (4th February 2018) Authors: Porksen, Niels K.; Linnebjerg, Helle; Lam, Eric Chen Quin; Garhyan, Parag; Pachori, Alok; Pratley, Richard E.; Smith, Steven R. Journal: Diabetes, obesity & metabolism Issue: Volume 20:Issue 5(2018) Page Start: 1193 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Development and Qualification of a Drug‐Disease Modeling Platform to Characterize Clinically Relevant Endpoints in Type 2 Diabetes Trials. Issue 4 (1st February 2018) Authors: Gaitonde, Puneet; Hurtado, Felipe K.; Garhyan, Parag; Chien, Jenny Y.; Schmidt, Stephan Journal: Clinical pharmacology & therapeutics Issue: Volume 104:Issue 4(2018) Page Start: 699 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Development and Verification of a Body Weight–Directed Disease Trial Model for Glucose Homeostasis. (7th September 2020) Authors: Farhan, Nashid; Gebert, Ines; Xing, Yifan; Wieser, Katharina; Lingineni, Karthik; Ma, Xiaosu; Chien, Jenny Y.; Garhyan, Parag; Schmidt, Stephan Journal: Journal of clinical pharmacology Issue: Volume 61:Number 2(2021) Page Start: 234 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Dose Unit Establishment for a New Basal Insulin Using Joint Modeling of Insulin Dose and Glycemic Response. (January 2018) Authors: Qu, Yongming; Luo, Junxiang; Garhyan, Parag; Antalis, Caryl J.; Chang, Annette M.; Jacober, Scott J. Journal: Journal of diabetes science and technology Issue: Volume 12:Number 1(2018:Jan.) Page Start: 155 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Evaluation of Insulin Lispro Pharmacokinetics and Pharmacodynamics Over 10 Days of Continuous Insulin Infusion in People With Type 1 Diabetes. (March 2023) Authors: Garhyan, Parag; Pratt, Edward; Klein, Oliver; Famulla, Susanne; Zijlstra, Eric; Lalonde, Amy; Swinney, Monica; Kazda, Christof; Dassau, Eyal Journal: Journal of diabetes science and technology Issue: Volume 17:Number 2(2023) Page Start: 274 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Novel hepato‐preferential basal insulin peglispro (BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetes. Issue 4 (7th February 2017) Authors: Porksen, Niels; Linnebjerg, Helle; Garhyan, Parag; Lam, Eric C. Q.; Knadler, Mary P.; Jacober, Scott J.; Hoevelmann, Ulrike; Plum‐Moerschel, Leona; Watkins, Elaine; Gastaldelli, Amalia; Heise, Tim Journal: Diabetes, obesity & metabolism Issue: Volume 19:Issue 4(2017) Page Start: 482 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Simulation-Based Evaluation of Dose Titration Algorithms for U-500R Insulin by Pump in Subjects with Type 2 Diabetes. (September 2021) Authors: Ma, Xiaosu; Waterhouse, Timothy; Ilag, Liza L.; Ly, Trang; Juneja, Rattan; Garhyan, Parag; Hardy, Thomas; Hood, Robert C. Journal: Journal of diabetes science and technology Issue: Volume 15:Number 5(2021) Page Start: 1195 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes. Issue 11 (8th June 2017) Authors: Guzman, Cristina B.; Zhang, Xiaotian M.; Liu, Rong; Regev, Arie; Shankar, Sudha; Garhyan, Parag; Pillai, Sreekumar G.; Kazda, Christof; Chalasani, Naga; Hardy, Thomas A. Journal: Diabetes, obesity & metabolism Issue: Volume 19:Issue 11(2017) Page Start: 1521 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Treatment with the glucagon receptor antagonist LY2409021 increases ambulatory blood pressure in patients with type 2 diabetes. Issue 8 (27th March 2017) Authors: Kazda, Christof M.; Frias, Juan; Foga, Irene; Cui, Xuewei; Guzman, Cristina B.; Garhyan, Parag; Heilmann, Cory; Yang, Jihui Anne; Hardy, Thomas A. Journal: Diabetes, obesity & metabolism Issue: Volume 19:Issue 8(2017) Page Start: 1071 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗